Aerie Pharmaceuticals Logo

News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
First Quarter Glaucoma Franchise Net Revenues of $29.8 Million , up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022 DURHAM, N.C.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
Abstracts showcase Rhopressa ® / netarsudil, AR-15512 and “ROCK’Ster” DURHAM, N.C. --(BUSINESS WIRE)--Apr. 26, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
Data adds to real-world use and clinical research on netarsudil (Rhopressa ® ) DURHAM, N.C. --(BUSINESS WIRE)--Apr. 20, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies,
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 6, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan , Chief Executive Officer, along with Peter Lang ,
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience DURHAM, N.C. --(BUSINESS WIRE)--Mar. 18, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2021 Glaucoma Franchise Net Revenues of $112.1 Million , an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32.7 Million , up 11% From Third Quarter Guidance of $130 Million to $140 Million in 2022 Glaucoma Franchise Forecasted Net Revenues, up 16% to 25% DURHAM, N.C.
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive b rings breadth of clinical development, medical affairs, strategy, and business development experience DURHAM, N.C. --(BUSINESS WIRE)--Feb. 24, 2022-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 17, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that its fourth quarter and full year 2021 financial results will
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 22, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
TOP